At present, the sGC stimulators or activators have been shown to possess a range of therapeutic effects, including the treatment of HF and PH (Koress et al., 2016; Zheng et al., 2018; Sandner et al., 2021a; Ruopp and Cockrill, 2022), as well as playing a protective role in kidney function (Stasch et al., 2015). This evidence concerns the gene SGCB and hydrops fetalis.